Erasca (ERAS) Capital Expenditures (2020 - 2026)
Erasca's (ERAS) quarterly Capital Expenditures came in at $36000.0 in Q1 2026, down 56.63% YoY from $83000.0 in Q1 2025, and up 300.0% on a QoQ basis from $9000.0 in Q4 2025.
Erasca (ERAS) Capital Expenditures (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Capital Expenditures data on file, last reported at $36000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 56.63% year-over-year to $36000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81000.0 (down 19.8% YoY) and the FY2025 annual result came in at $128000.0, up 113.33% from the prior year.
- Capital Expenditures advanced to $36000.0 in Q1 2026, from $9000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $7.3 million in Q1 2022 to a low of $5000.0 in Q3 2024.
- A 5-year average of $1.0 million and a median of $82500.0 in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures surged 5913.11% — and 2024, when it tumbled 97.92%.
- Tracing ERAS's Capital Expenditures over 5 years: stood at $864000.0 in 2022, then slumped by 90.51% to $82000.0 in 2023, then sank by 93.9% to $5000.0 in 2024, then soared by 80.0% to $9000.0 in 2025, then jumped by 300.0% to $36000.0 in 2026.
- The last three Capital Expenditures figures came in at $36000.0 (Q1 2026), $9000.0 (Q4 2025), and $6000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | 8,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8,000.00 |
| Jun 30, 2026 | 8,000.00 |
| Mar 31, 2026 | 36,000.00 |
| Mar 31, 2026 | 36,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Mar 31, 2024 | 42,000.00 |
| Mar 31, 2024 | 42,000.00 |
| Dec 31, 2023 | 82,000.00 |
| Dec 31, 2023 | 82,000.00 |